Literature DB >> 21116760

Prognostic significance of p53 protein expression in early gastric cancer.

Andrea Rodrigues Gonçalves1, Antonio Jose Vasconcellos Carneiro, Ivanir Martins, Paulo Antonio Silvestre de Faria, Maria Aparecida Ferreira, Eduardo Linhares Riello de Mello, Homero Soares Fogaça, Celeste Carvalho Siqueira Elia, Heitor Siffert Pereira de Souza.   

Abstract

Mutations of the p53 tumor suppressor gene have been associated with abnormalities in cell cycle regulation, DNA repair and synthesis, apoptosis, and it has been implicated in the prognosis of advanced gastric cancer. The aim of this study was to evaluate the occurrence of p53 gene mutation and its possible prognostic implications in early gastric cancer. In a retrospective study, we studied 80 patients with early gastric cancer treated surgically between 1982 and 2001. Mutation of p53 gene was investigated in surgical gastric specimens by immunohistochemistry, and results were analyzed in relation to gender, age, macroscopic appearance, size and location of tumor, presence of lymph nodes, Lauren's histological type, degree of differentiation, and the 5-year survival. The expression of p53 was more frequent among the intestinal type (p = 0.003), the differentiated (p = 0.007), and the macroscopically elevated tumors (p = 0.038). Nevertheless, the isolated expression of p53 was not associated with the 5-year survival, or with the frequency of lymph node involvement. The degree of differentiation was detected as an independent factor related to the outcome of patients (0.044). Significantly shorter survival time was found in p53-negative compared with p53-positive patients, when considering the degree of differentiation of tumors, as assessed by Cox regression analysis (0.049). The association of p53 with the intestinal type, the degree of differentiation and morphological characteristics, may reflect the involvement of chronic inflammatory process underlying early gastric cancer. In this population sample, the expression of p53 alone has no prognostic value for early gastric cancer. However, the significant difference in p53 expression between subgroups of degree of differentiation of tumors can influence post-operative outcome of patients and may be related to possible distinct etiopathogenic subtypes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21116760     DOI: 10.1007/s12253-010-9333-z

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  50 in total

Review 1.  Molecular biological observations in gastric cancer.

Authors:  E Tahara; S Semba; H Tahara
Journal:  Semin Oncol       Date:  1996-06       Impact factor: 4.929

Review 2.  Assessing TP53 status in human tumours to evaluate clinical outcome.

Authors:  T Soussi; C Béroud
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

Review 3.  Gastric cancer: global pattern of the disease and an overview of environmental risk factors.

Authors:  D Forman; V J Burley
Journal:  Best Pract Res Clin Gastroenterol       Date:  2006       Impact factor: 3.043

4.  Mutations of p53 gene in gastric carcinoma in Taiwan.

Authors:  J Y Wang; S R Lin; J S Hsieh; C H Hsu; Y S Huang; T J Huang
Journal:  Anticancer Res       Date:  2001 Jan-Feb       Impact factor: 2.480

Review 5.  Tumor growth patterns and biological characteristics of early gastric carcinoma.

Authors:  Y Maehara; Y Kakeji; S Oda; H Baba; K Sugimachi
Journal:  Oncology       Date:  2001       Impact factor: 2.935

6.  Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries.

Authors:  A A Botterweck; L J Schouten; A Volovics; E Dorant; P A van Den Brandt
Journal:  Int J Epidemiol       Date:  2000-08       Impact factor: 7.196

7.  Cellular and molecular pathology of gastric carcinoma and precursor lesions: A critical review.

Authors:  Si-Chun Ming
Journal:  Gastric Cancer       Date:  1998-12       Impact factor: 7.370

Review 8.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

9.  Overexpression of p53 in different subtypes of intestinal metaplasia and gastric cancer.

Authors:  M S Wu; C T Shun; W C Lee; C J Chen; H P Wang; W J Lee; J C Sheu; J T Lin
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

10.  Prognostic value of p53 protein expression for patients with gastric cancer--a multivariate analysis.

Authors:  Y Maehara; M Tomoda; S Hasuda; A Kabashima; E Tokunaga; Y Kakeji; K Sugimachi
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

View more
  11 in total

1.  Antral atrophy, intestinal metaplasia, and preneoplastic markers in Mexican children with Helicobacter pylori-positive and Helicobacter pylori-negative gastritis.

Authors:  Rodolfo Villarreal-Calderon; Arturo Luévano-González; Mariana Aragón-Flores; Hongtu Zhu; Ying Yuan; Qun Xiang; Benjamin Yan; Kathryn Anne Stoll; Janet V Cross; Kenneth A Iczkowski; Alexander Craig Mackinnon
Journal:  Ann Diagn Pathol       Date:  2014-02-11       Impact factor: 2.090

2.  Predictable factors for lymph node metastasis in early gastric cancer analysis of clinicopathologic factors and biological markers.

Authors:  Yi-Wei Wang; Mei-Ling Zhu; Rui-Fen Wang; Wen-Ji Xue; Xue-Ru Zhu; Li-Feng Wang; Lei-Zhen Zheng
Journal:  Tumour Biol       Date:  2016-01-05

3.  Different effects of p53 protein overexpression on the survival of gastric cancer patients according to Lauren histologic classification: a retrospective study.

Authors:  Ki Wook Kim; Nayoung Kim; Yonghoon Choi; Won Seok Kim; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Dong Ho Lee; Young Suk Park; Sang-Hoon Ahn; Do Joong Park; Hyung-Ho Kim; Hye Seung Lee; Ji-Won Kim; Jin Won Kim; Keun-Wook Lee; Won Chang; Ji Hoon Park; Yoon Jin Lee; Kyoung Ho Lee; Young Hoon Kim
Journal:  Gastric Cancer       Date:  2021-02-18       Impact factor: 7.370

4.  Biomarkers for gastric cancer: Progression in early diagnosis and prognosis (Review).

Authors:  Ziliang Jin; Weihua Jiang; Liwei Wang
Journal:  Oncol Lett       Date:  2015-02-12       Impact factor: 2.967

5.  Clinicopathological and prognostic significance of Ki-67, caspase-3 and p53 expression in gastric carcinomas.

Authors:  Li-Jun Xiao; Shuang Zhao; En-Hong Zhao; Xin Zheng; Wen-Feng Gou; Yasuo Takano; Hua-Chuan Zheng
Journal:  Oncol Lett       Date:  2013-08-19       Impact factor: 2.967

6.  Helicobacter pylori and Molecular Markers as Prognostic Indicators for Gastric Cancer in Korea.

Authors:  Hee Jin Kim; Sung Wook Hwang; Nayoung Kim; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Dong Ho Lee; Do Joong Park; Hyung Ho Kim; Joo Sung Kim; Hyun Chae Jung; Hye Seung Lee
Journal:  J Cancer Prev       Date:  2014-03

7.  Discrimination of p53 immunohistochemistry-positive tumors by its staining pattern in gastric cancer.

Authors:  Koji Ando; Eiji Oki; Hiroshi Saeki; Zhao Yan; Yasuo Tsuda; Gen Hidaka; Yuta Kasagi; Hajime Otsu; Hiroyuki Kawano; Hiroyuki Kitao; Masaru Morita; Yoshihiko Maehara
Journal:  Cancer Med       Date:  2014-10-30       Impact factor: 4.452

8.  Comparison between Resectable Helicobacter pylori-Negative and -Positive Gastric Cancers.

Authors:  Hee Jin Kim; Nayoung Kim; Hyuk Yoon; Yoon Jin Choi; Ju Yup Lee; Yong Hwan Kwon; Kichul Yoon; Hyun Jin Jo; Cheol Min Shin; Young Soo Park; Do Joong Park; Hyung Ho Kim; Hye Seung Lee; Dong Ho Lee
Journal:  Gut Liver       Date:  2016-03       Impact factor: 4.519

9.  Clinical Significance of p53 Protein Expression, Beta-catenin Expression and HER2 Expression for Epstein-Barr Virus-associated Gastric Cancer.

Authors:  Dong Won Baek; Byung Woog Kang; Soyoon Hwang; Jong Gwang Kim; An Na Seo; Han Ik Bae; Oh Kyoung Kwon; Seung Soo Lee; Ho Young Chung; Wansik Yu
Journal:  Chonnam Med J       Date:  2017-05-25

Review 10.  The Pattern of Signatures in Gastric Cancer Prognosis.

Authors:  Julita Machlowska; Ryszard Maciejewski; Robert Sitarz
Journal:  Int J Mol Sci       Date:  2018-06-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.